
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Michael J. Mauro, provides an overview of some of the questions he hears from patients with chronic myeloid leukemia (CML).
Michael J. Mauro, leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, provides an overview of some of the questions he hears from patients with chronic myeloid leukemia (CML).






